Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Inventory (2016 - 2025)

Historic Inventory for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to $2.7 million.

  • China Pharma Holdings' Inventory rose 971.11% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 971.11%. This contributed to the annual value of $2.8 million for FY2024, which is 2645.59% down from last year.
  • Per China Pharma Holdings' latest filing, its Inventory stood at $2.7 million for Q3 2025, which was up 971.11% from $2.7 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Inventory high stood at $3.9 million for Q2 2023, and its period low was $2.5 million during Q3 2024.
  • Over the past 5 years, China Pharma Holdings' median Inventory value was $3.0 million (recorded in 2021), while the average stood at $3.2 million.
  • Its Inventory has fluctuated over the past 5 years, first surged by 3101.14% in 2023, then plummeted by 3366.49% in 2024.
  • Quarter analysis of 5 years shows China Pharma Holdings' Inventory stood at $2.9 million in 2021, then changed by 0.0% to $2.9 million in 2022, then surged by 31.01% to $3.9 million in 2023, then dropped by 26.46% to $2.8 million in 2024, then dropped by 3.48% to $2.7 million in 2025.
  • Its Inventory stands at $2.7 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.